FG
PCRX icon

Formula Growth’s Pacira BioSciences PCRX Stock Holding History

Formula Growth’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-42,832
Closed -$2.28M – 143
2022
Q3 		$2.28M Buy
42,832
+3,666
+9% +$204K 0.65% 68
2022
Q2 		$2.28M Hold
39,166
– – 0.63% 62
2022
Q1 		$2.99M Sell
39,166
-672
-2% -$44.8K 0.56% 66
2021
Q4 		$2.4M Sell
39,838
-16,800
-30% -$926K 0.43% 75
2021
Q3 		$3.17M Hold
56,638
– – 0.45% 73
2021
Q2 		$3.44M Hold
56,638
– – 0.47% 67
2021
Q1 		$3.97M Buy
+56,638
New +$4.05M 0.57% 56

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Formula Growth's PCRX Position: Q4 2022 in Review

Formula Growth sold out of Pacira BioSciences (PCRX) in Q4 2022, closing a stake of 42,832 shares — an estimated $2.28M sold.

Formula Growth first reported a position in PCRX in Q1 2021 and held it in 7 quarters. The position peaked at $3.97M in Q1 2021. 273 funds tracked by Wall St. Rank hold PCRX as of Q4 2022.

  • Formula Growth reported no remaining Pacira BioSciences position as of Q4 2022 after selling out during the quarter.
  • Formula Growth sold 42,832 Pacira BioSciences shares in Q4 2022, an estimated $2.28M.
  • Formula Growth first reported a position in Pacira BioSciences in Q1 2021 and held it in 7 quarters.
  • Formula Growth's Pacira BioSciences position peaked at $3.97M in Q1 2021.
  • 273 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2022.

Based on Formula Growth's 13F filing for Q4 2022, filed 13 Feb 2023.